Clinical efficacy of rhIL-11

ONCOLOGY

Volumn 14, Issue 9 SUPPL. 8, 2000, Pages 32-40

  Reynolds, Craig H ^a  

^a US Oncology Ocala Oncology Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 11; RECOMBINANT COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; BONE MARROW; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INTERACTION; FEMALE; HEMATOPOIESIS; HUMAN; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PLATELETS; BONE MARROW; BREAST NEOPLASMS; COLONY-STIMULATING FACTORS, RECOMBINANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; HUMANS; INTERLEUKIN-11; MIDDLE AGED; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0034280613     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al: A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 87:3615-3624, 1996.
2. Tepler I, Elias L, Smith JW 2nd, et al: A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87:3607-3614, 1996.
3. Isaacs C, Robert NJ, Bailey FA, et al: Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 15:3368-3377, 1997.
4. Bracho F, Krailo M, Blazar BE, et al: Comparison of the clinical and hematological effects of PIXY321, IL-11 + G-CSF and IL-6 + G-CSF on children with recurrent solid tumors: IL-11 + G-CSF best enhances hematopoietic reconstitution and CD34+ recovery (abstract). Blood 92(suppl 1):398a, 1998.
5. Bracho F, Krailo M, Blazar BE, et al: Clinical and hematological recovery in children with recurrent/refractory solid tumors treated with ifosfamide/carboplatin, and etoposide (ICE) followed by sequential trials of IL-11/G-CSF, IL-6/G-CSF, P1XY321, or G-CSF: Children's Cancer Group (CCG) and Genetics Institute experience (abstract 160). Proc Am Soc Clin Oncol 18:43a, 1999.
6. Data on file, Genetics Institute, Cambridge, Mass.
7. Kaye JA: FDA licensure of Neumega to prevent severe chemotherapy-induced thrombocytopenia. Stem Cells 16:207-233, 1998.
8. Kaye JA, Loewy J, Blume J, et al: Recombinant human interleukin-11 (Neumega, rhIL-11 growth factor) increases plasma von Willebrand factor and fibrinogen concentrations in normal human subjects (abstract). Blood 84:276a, 1994.
9. Du X, Williams DA: Interleukin-11: review of molecular, cell biology, and clinical use. Blood 89:3897-3908, 1997.
10. Ault K, Mitchell J, Knowles C: Recombinant human interleukin eleven (Neumega rhIL-11 growth factor) increases plasma volume and decreases urine sodium excretion in normal human subjects (abstract). Blood 84:276a, 1994.
11. Frank J, O'Grady M, Abrams-Ogg A, et al: The effects of interleukin-11 on cardiovascular parameters in the dog. J Vet Intern Med 12:198, 1998.
12. Ravelli F, Allessie M: Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 96:1686-1695, 1997.
13. Smith II JW, Beach K, Bedrosian CL, et al: Neumega (Oprelvekin; rhIL-11) prevents severe chemotherapy-induced thrombocytopenia in abbreviated phase 3 study (abstract). Blood 92:317a, 1998.
14. Elias A, Ryan L, Aisner J, et al: Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. Semin Oncol 17:41-49, 1990.
15. Krigel RL, Palackdharry CS, Padavic K, et al: Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: A phase I study with apparent activity in non-small-cell lung cancer. J Clin Oncol 12:1251-1258, 1994.
16. Boni C, Cocconi G, Bisagni G, et al: Cis-plalin and etoposide (VP-16) as a single regimen for small cell lung cancer. A phase II trial. Cancer 63:638-642, 1989.
17. Felting JH, Gray R, Fairclough DL, et al: Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor- negative breast cancer: An Intergroup study. J Clin Oncol 16:2382-2391, 1998.
18. Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 332:901-906, 1995.
19. van Rijswijk RE, Haanen C, Dekker AW, et al: Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol 7:1776-1782, 1989.